|
Title
|
|
|
|
Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Vaccination with recombinant hepatitis B vaccines is highly effective in preventing hepatitis B infection. Recently, a preservative-free (PF) formulation of hepatitis B vaccine [GlaxoSmithKline (GSK) Biologicals, Rixensart, Belgium] has been licensed. The immunogenicity of the PF hepatitis B vaccine and antibody persistence 6 years later was assessed in this study. This formulation was compared with the preservative- containing (PC) formulation of the vaccine and a low-preservative (LP) content formulation. Five hundred forty-one healthy adult subjects were evaluated in the primary study. Over 94% of the subjects in the three study groups had seroprotective anti-HBs antibody concentrations (10 mIU/ml) 1 month after completing primary vaccination. Antibody measurements in 242 healthy adults who returned for the follow-up study and who had received primary vaccination 6 years earlier showed that over 81% of subjects in the three study groups still had anti-HBs antibody concentrations 10 mIU/ml. No apparent differences in antibody decline or distribution between the study groups were observed. These results indicate that the removal of preservatives from the hepatitis B vaccine does not affect adversely its immunogenicity both in the short and in the longer term. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal of medical virology. - New York, N.Y.
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2009
| |
|
ISSN
|
|
|
|
0146-6615
| |
|
DOI
|
|
|
|
10.1002/JMV.21568
| |
|
Volume/pages
|
|
|
|
81
:10
(2009)
, p. 1710-1715
| |
|
ISI
|
|
|
|
000269395400004
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|